RECRUITING

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

Talk to us

Conditions

Blood CancerLeukemia

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.

Official Title

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

Quick Facts

Study Start:2024-12-09
Study Completion:2028-01-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06469307

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 or older
  2. * English speaking
  3. * Ability to understand and willingness to provide oral consent
  4. * DFCI patient who are in remission from a blood cancer \>1 year will be preferred.
  1. * Adults unable to consent
  2. * Individuals who are not yet adults (infants, children, teenagers \<18 years old)
  3. * Prisoners.
  4. * Unwilling/unable to agree to maintaining the confidentiality of reviews and clinical trial materials, as outlined in Section 9.1
  5. * Note 1: Patients and non-patient community members who are pregnant are eligible. This is a non-interventional study that meets the definition of minimal risk and poses no greater risk to pregnant individuals or fetuses. Pregnancy status will not be assessed.
  6. * Note 2: English fluency is necessary as protocols being reviewed are written in English and cannot be feasibly translated to other languages within the time period necessary to complete timely reviews.

Contacts and Locations

Study Contact

Andrew Hantel, MD
CONTACT
617-582-9394
Andrew_Hantel@dfci.harvard.edu
Thomas Walsh, MPH
CONTACT
857-215-2365
thomasp_walsh@dfci.harvard.edu

Principal Investigator

Andrew Hantel, MD
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Andrew Hantel, MD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-09
Study Completion Date2028-01-01

Study Record Updates

Study Start Date2024-12-09
Study Completion Date2028-01-01

Terms related to this study

Keywords Provided by Researchers

  • Blood Cancer
  • Leukemia

Additional Relevant MeSH Terms

  • Blood Cancer
  • Leukemia